| Previous Close | 33.360 |
| Open | 33.290 |
| Bid | 33.280 x 1100 |
| Ask | 33.290 x 8900 |
| Day's Range | 33.250 - 33.450 |
| 52 Week Range | 29.830 - 35.380 |
| Volume | 2,281,612 |
| Avg. Volume | 18,956,709 |
| Market Cap | 199.08B |
| Beta | 1.05 |
| PE Ratio (TTM) | 28.08 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.84%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Market Realist•3 hours ago
How Amgen’s Nephrology Drugs Are Positioned after 2Q17?
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
- InvestorPlace•yesterday
The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak
Giving credit where credit is due, I do think Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock looks stronger than it did just a couple of quarters ago. VRX stock has still declined 1.5% so far this year, but the narrative surrounding the company has certainly changed. On the Q2 conference call, Valeant management made a big deal of the fact that 73% of Q2 revenue came from Bausch & Lomb and the Salix business.
- Market Realist•2 days ago
Pfizer’s Corporate and Pipeline Developments in 2Q17
Apart from Pfizer’s (PFE) product developments, let's take a look at some recent pipeline and corporate developments.
